Flinton Capital Management’s Sage Therapeutics SAGE Stock Holding History

Flinton Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$539K	Hold	3,842	–	–	0.02%	436
2019 Q2	$703K	Buy	3,842 +170	+5%	+$29K	0.02%	391
2019 Q1	$584K	Buy	3,672 +476	+15%	+$68.9K	0.02%	432
2018 Q4	$306K	Sell	3,196 -204	-6%	-$23.3K	0.01%	551
2018 Q3	$480K	Buy	3,400 +2,720	+400%	+$420K	0.01%	504
2018 Q2	$106K	Buy	680 +646	+1,900%	+$101K	﹤0.01%	759
2018 Q1	$5K	Buy	+34	New	+$5.77K	﹤0.01%	849

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Flinton Capital Management's SAGE Position: Q3 2019 in Review

Flinton Capital Management held its Sage Therapeutics (SAGE) position steady in Q3 2019 at 3,842 shares worth $539K. The position accounts for 0.02% of the portfolio, ranked #436.

Flinton Capital Management first reported a position in SAGE in Q1 2018 and has held it in 7 quarters since. The position peaked at $703K in Q2 2019. 284 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

Flinton Capital Management held 3,842 shares of Sage Therapeutics worth $539K as of Q3 2019.
Flinton Capital Management left its Sage Therapeutics share count unchanged in Q3 2019.
Sage Therapeutics made up 0.02% of Flinton Capital Management's portfolio in Q3 2019, its #436 holding.
Flinton Capital Management first reported a position in Sage Therapeutics in Q1 2018 and has held it in 7 quarters since.
Flinton Capital Management's Sage Therapeutics position peaked at $703K in Q2 2019.
284 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.